References
- Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378:321–330.
- 2018 Alzheimer’s disease facts and figures. [cited 2018 Jun 11]. Available from: https://www.alz.org/facts/overview.asp
- Mo -J-J, Li J-Y, Yang Z, et al. Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer’s disease: a systematic review and network meta-analysis. Ann Clin Transl Neurol. 2017;4:931–942.
- Liu E, Schmidt ME, Margolin R, et al. Amyloid-β 11C-PiB-PET imaging results for 2 randomized bapineuzumab phase 3 AD trials. Neurology. 2015;85:692–700.
- Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 1014;370:322–333.
- Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198–207.
- Ostrowitzki S, Lasser RA, Dorflinger E, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2017;9:95.
- Cummings JL, Cohen S, van Dyck CH, et al. ABBY: A phase 2 randomized trial of crenazumab in mild to moderate Alzheimer disease. Neurology. 2018;22:e1889–97.
- DeMattos RB, Bales K, Cummins DJ, et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA. 2001;98:8850–8855.
- Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement. 2012;8:261–271.
- Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311–321.
- Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement. 2016;12:110–120.
- FierceBiotech. Alzheimer’s hopes dashed as Lilly gives up on amyloid drug solanezumab. [cited 2018 Jun 11]. Available from: https://www.fiercebiotech.com/biotech/alzheimer-s-hopes-dashed-as-lilly-gives-up-amyloid-drug-solanezumab
- Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537:50–56.
- Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–185.
- Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;6:794–799.
- Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis; time, space, and “wingmen”. Nat Neurosci. 2015;18:800–806.
- Donohue MC, Sperling RA, Petersen R, et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317:2305–2316.
- Donovan NJ, Locascio JJ, Marshal GA, et al. Longitudinal association of amyloid beta and anxious-depressive symptoms in cognitively normal older adults. Am J Psychiatry. 2018;176:530–537.
- A study of solanezumab (LY2062430) in participants with prodomal Alzheimer’s disease (ExpeditionPRO). Clinical Trials,gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02760602?cond=prodromal+Alzheimer&draw=2&rank=4